AGIOS PHARMACEUTICALS, INC. - 10-Q Filing
Agios Pharmaceuticals reports Q3 2026 financial results including detailed breakdown of Vorasidenib royalty rights and segment performance.
Tickers: $AGIO
Agios Pharmaceuticals reports Q3 2026 financial results including detailed breakdown of Vorasidenib royalty rights and segment performance.
Tickers: $AGIO